BAYAN A. ALZUMAILI, MD

Plain English
This study looked at patients with sporadic medullary thyroid carcinoma to understand how having multiple tumors (multifocality) affects their health outcomes compared to those with a single tumor (unifocal). Researchers found that out of 270 patients, 63 had multifocal tumors, and no significant differences in tumor grade, survival rates, or key mutations were observed between the two groups. Specifically, both groups had similar overall survival rates after 15 years, and multifocal tumors were often smaller, averaging about 0.60 cm in size. Who this helps: This research helps doctors better understand the implications of multifocality in thyroid cancer and can aid in treatment decisions for patients.

Plain English
This study looked at 52 thyroid nodules with specific genetic mutations to see how often they were cancerous. Among the nodules tested, 65% turned out to be malignant, with varying risks depending on the type of mutations present. This research matters because it highlights that many nodules with certain mutations can be benign, suggesting that less invasive treatments could be appropriate for patients, rather than the total thyroid removal usually recommended. Who this helps: This information benefits patients with thyroid nodules and their doctors by reducing unnecessary surgeries.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
This study looked at the genetic changes in medullary thyroid carcinoma (MTC) among 290 patients to see how these changes relate to tumor characteristics and patient outcomes. They found that 16.3% of the patients had inherited mutations, while 46.9% had acquired mutations. Some mutations were linked to larger tumors and worse survival rates; specifically, a certain mutation was associated with a shorter time without distant spread of the cancer and decreased overall survival. Who this helps: This research benefits patients with medullary thyroid carcinoma as it provides insights into their prognosis and potential treatment paths.

Plain English
Researchers developed a new tool, called a nomogram, to predict how long patients with medullary thyroid carcinoma (MTC) can remain cancer-free after treatment. They analyzed data from 300 patients and found that their model is highly accurate, with a predictive ability score of 0.94 and 0.9 when tested on another group of 87 patients. This tool can help doctors make better treatment decisions for MTC patients, improving their chances of avoiding a recurrence. Who this helps: This benefits patients with medullary thyroid carcinoma and their doctors.

Plain English
This study examined a rare type of cancer in the tongue of a 46-year-old man, which was driven by a specific genetic mutation known as the FUS::CREM fusion. The tumor was about 4 cm in size and displayed aggressive features, although it had not spread to nearby lymph nodes. After surgery and radiation treatment, the patient showed no signs of the cancer returning after four months. Who this helps: This information is valuable for doctors treating patients with rare head and neck cancers.

Plain English
The researchers studied a specific genetic mutation, RAS p.Q61R, in 217 thyroid nodules to see how common it is and how it relates to cancer risk. They found that this mutation appears in a significant percentage of thyroid nodules, but most of the tumors associated with it are low-risk and do not lead to serious health issues. This is important because it shows a reliable and quick way to identify these mutations, helping doctors decide how to monitor and treat patients with thyroid nodules.

Plain English
Researchers looked at 5,030 thyroid cancer samples and found 17 tumors with mutations in a specific gene family—11 where this mutation was the main cancer driver and 6 where it was a secondary mutation that might help cancer resist treatment. They discovered that some of these mutations could be targeted with existing drugs, but doctors aren't currently looking for them because they're not well-known. This matters because identifying these mutations in thyroid cancer patients could open up new treatment options that don't work for other types of thyroid cancer, potentially improving outcomes for people who have these specific mutations.

Plain English
This research paper looks at a specific type of cancer found in the nose and sinuses called IDH2-mutated sinonasal tumors. The study found that out of 82 cases, these tumors often occur in patients around 60 years old, with the tumors typically measuring about 5 cm. While most patients (65%) can have their tumors surgically removed, there is still a high chance of recurrence and metastasis (60% and 40%, respectively), but patients with this mutation tend to have better outcomes compared to others without it. Who this helps: Patients with IDH2-mutated sinonasal tumors and their doctors.

Plain English
This study looked at a specific type of thyroid cancer called diffuse sclerosing papillary thyroid carcinoma (DS-PTC) and compared it with two other forms of thyroid cancer: classic and tall cell papillary thyroid cancer. Researchers found that patients with DS-PTC were generally younger and had more severe disease than those with the other types. Specifically, 50.4% of DS-PTC patients experienced a recurrence of their cancer within five years, compared to only 92.4% of classic and 88.4% of tall cell patients. Despite the high recurrence rate, patients with DS-PTC had a 100% chance of still being alive ten years after diagnosis if they received successful treatment. Who this helps: This helps patients with diffuse sclerosing papillary thyroid carcinoma and their doctors by providing valuable insights into the cancer's behavior and prognosis.

Plain English
This research paper looks at how advances in molecular testing are changing the diagnosis and treatment of thyroid nodules, which are common lumps in the thyroid gland. While fine needle aspiration biopsies can help identify cancer, results are unclear in about 30% of cases, leading to the need for more tests. The study highlights that new genetic testing methods are now essential for managing thyroid cancer, offering clearer information for doctors and personalized treatment options for patients. Who this helps: This helps patients with thyroid nodules and thyroid cancer.

Plain English
This study looked at different ways to grade mucoepidermoid carcinoma (a type of salivary gland cancer) to see if a simpler two-tier system could work better than the current three-tier systems. Researchers analyzed data from 262 patients and found that high-grade tumors had a 25% risk of spreading to lymph nodes and a 76% chance of surviving without recurrence over five years, compared to 7% for low-grade tumors, who had a 97% five-year recurrence-free survival rate. These findings support using a simpler, two-tiered grading system, which could make it easier for doctors to predict patient outcomes and tailor treatment plans. Who this helps: This helps patients and doctors by providing clearer prognostic information.

Plain English
This study looked at different methods for counting the Ki67 index, a marker used to evaluate how quickly cancer cells are growing in medullary thyroid carcinoma, a type of thyroid cancer. Researchers found that three alternative counting methods—an experienced investigator's visual assessment, a machine learning algorithm, and specialized image analysis—produced results that closely matched the traditional manual counting method, with a high correlation rate above 88%. This is important because faster and easier ways to assess cancer growth could lead to better monitoring and treatment strategies for patients, especially those with aggressive forms of the disease. Who this helps: This helps patients with medullary thyroid carcinoma and their doctors.

Plain English
Researchers studied a type of thyroid tumor called noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) to better understand its diagnosis and treatment. They found that NIFTP rarely led to cancer recurrence after surgery, but the way it was diagnosed often varied, leading to uncertainty in treatment decisions. This highlights the need for clearer guidelines for managing these borderline tumors, which can help doctors take more consistent and effective actions for their patients.

Plain English
This study focused on medullary thyroid carcinoma (MTC), a serious type of thyroid cancer. Researchers analyzed tumor samples from 327 patients and created a new, simpler grading system that classifies MTC as high-grade if it has specific aggressive features; they found that 24.8% of the tumors examined were high-grade. This new system helps predict how well patients will do after diagnosis and aligns MTC grading with other types of neuroendocrine tumors, making it easier for doctors to apply in treatment. Who this helps: This benefits patients diagnosed with medullary thyroid carcinoma and their doctors.

Plain English
This study looked at 705 cases of pleomorphic adenoma (PA), a benign tumor that can come back after treatment. Researchers found that 3.4% of primary tumors returned, with factors like being younger than 30 years, having a high number of cell divisions, and poor initial removal linked to higher chances of recurrence. For recurrent cases, nearly half of the patients had further recurrences, especially within 10 years, and those who received radiotherapy had better outcomes. Who this helps: Patients with pleomorphic adenoma and their doctors.

Plain English
This study focused on acinic cell carcinoma (AciCC), a type of salivary gland cancer that can be either low or high-grade, impacting survival rates. Researchers analyzed 117 cases and found that high-grade AciCCs had a much lower 5-year survival rate of 50%, compared to 100% for low or intermediate grades. They also proposed a new grading system to improve cancer diagnosis and treatment planning, with the NR4A3 stain being very effective, identifying AciCC with 96% sensitivity and 93% specificity. Who this helps: Patients with salivary gland tumors and their doctors.

Plain English
This study focused on the impact of extranodal extension (ENE) in patients with HPV-positive throat cancer who had undergone surgery. Researchers looked at 232 patients and found that 24% had ENE, which was linked to worse outcomes. Specifically, patients with ENE had a 5-year survival rate of 64%, compared to 95% for those without ENE, highlighting how ENE is an important factor in predicting patient survival. Who this helps: This benefits patients with HPV-positive throat cancer and their doctors.

Plain English
This study looked at 222 young patients (aged 21 and under) with a type of thyroid cancer. Researchers found that while most pediatric thyroid cancers have a good chance of recovery, certain types, especially those with widespread lymph node involvement or tissue damage, showed worse outcomes, with only 77% remaining disease-free after 10 years. Notably, one aggressive cancer type was linked to a higher risk of complications and advanced disease spread. Who this helps: This research benefits doctors and pediatric patients by providing a clearer understanding of which thyroid cancers may pose greater risks and need closer monitoring.

Plain English
This research focused on young patients with oral squamous cell carcinoma (OSCC), analyzing 150 cases from individuals aged 40 or younger. The study found that 63% of these patients were non-smokers, and most tumors were located on the oral tongue. Young patients (30 years old or younger) had poorer survival rates and disease-specific survival compared to older young patients, highlighting age and tumor characteristics as important factors in patient outcomes. Who this helps: This information benefits doctors and young patients dealing with oral cancer by providing insights into risk factors and prognosis.

Plain English
This study examined a rare type of head and neck cancer called spindle cell squamous cell carcinoma (SpC-SCC), which represents a small percentage of head and neck cancers, studying 71 cases. The research found that many patients were older men, often with a history of smoking, and the average survival rates were concerning: only 62% survived three years, dropping to just 12% after ten years. Understanding the characteristics of this cancer can help doctors evaluate the prognosis and tailor treatment, especially since certain features appeared to influence survival rates. Who this helps: Patients with head and neck spindle cell squamous cell carcinoma and their doctors.

Plain English
Researchers studied medullary thyroid carcinoma (MTC), a rare type of thyroid cancer, to create a grading system that could help predict patient outcomes. They found that the presence of tumor necrosis and a high mitotic rate (5 or more dividing cells) significantly indicated worse outcomes for patients, with 20% of tumors showing necrosis and 5% having a high mitotic index. This grading system will assist doctors in better assessing and treating patients based on their specific risk levels after surgery. Who this helps: This helps patients with medullary thyroid carcinoma by providing clearer treatment strategies and follow-up care.

Plain English
This study looked at a type of aggressive cancer called salivary duct carcinoma (SDC) and how certain immune markers are expressed in it. Researchers found that 83% of the SDC samples tested positive for a specific tumor marker (PRAME), and 66% showed positive levels of PD-L1, a protein that can help tumors evade the immune system. These findings suggest that targeting these markers with new immune therapies, like cancer vaccines or treatments that block PD-1/PD-L1 interactions, could improve outcomes for patients with this challenging cancer. Who this helps: This helps patients with salivary duct carcinoma.

Plain English
This study looked at 235 cases of a specific type of thyroid cancer to better understand how the amount of papillary growth (tiny projections in the tumors) affects the likelihood of the cancer spreading to lymph nodes. They found that 27 patients (12%) had cancer that had spread, and almost all of those cases (89%) had 50% or more papillae. This is important because it supports keeping a diagnosis criterion that states if there are less than 1% papillae, the tumor can be classified as a non-invasive type, which can help avoid unnecessary treatments for patients at low risk. Who this helps: This helps patients with low-risk thyroid tumors by reducing unnecessary treatments.

Plain English
This study looked at a rare case of a 56-year-old man who had both clear cell and papillary kidney cancer in the same kidney. Researchers found that having both types of tumors together is uncommon, but they reviewed literature that shows this occurs in a small number of cases. This matters because understanding these rare occurrences can help doctors better diagnose and treat patients with complicated kidney conditions. Who this helps: This helps patients with kidney cancer and their doctors.

Plain English
This study looked at a rare condition called lymphangioma circumscriptum (LC) that affects the tongue. The researchers reported a specific case where a middle-aged man had a painless growth on his tongue that showed significant bleeding. Understanding this condition is important for doctors to accurately diagnose and treat similar cases in the future. Who this helps: This helps doctors and patients with tongue growths or lymphatic disorders.